Cell Therapeutics Hits New 52-Week High at $2.21 (CTIC)
Shares of Cell Therapeutics (NASDAQ:CTIC) hit a new 52-week high during trading hours on Friday, Stock Ratings Network.com reports. The company traded as high as $2.21 and last traded at $2.17, with a volume of 6,365,695 shares trading hands. The stock had previously closed at $1.99.
CTIC has been the subject of a number of recent research reports. Analysts at HC Wainwright initiated coverage on shares of Cell Therapeutics in a research note to investors on Monday, November 4th. They set a “buy” rating and a $4.00 price target on the stock. Separately, analysts at Janney Montgomery Scott initiated coverage on shares of Cell Therapeutics in a research note to investors on Tuesday, October 29th. They set a “buy” rating on the stock. Finally, analysts at Wells Fargo & Co. reiterated a “positive” rating on shares of Cell Therapeutics in a research note to investors on Monday, October 7th.
Cell Therapeutics has a one year low of $0.97 and a one year high of $2.17. The stock has a 50-day moving average of $1.86 and a 200-day moving average of $1.47. The company’s market cap is $244.2 million.
Cell Therapeutics, Inc develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.